Protherics PLC
Notification of PDMR Interests
London, UK; Brentwood, TN, US; 12 June 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, today announces that, on 11 June 2007, the following options
over ordinary shares in the Company ("Ordinary Shares") were granted under the
terms of the Protherics PLC Long Term Incentive Plan at an exercise price of 2
pence per share:
Name Position Number of
Options
Ian Scoular Director of Business Development 136,170
Nicholas Staples Director of Corporate Affairs 114,893
Sally Waterman Director of Research & Development 136,170
In addition, the following options were granted on 11 June 2007 under the terms
of the Protherics PLC Deferred Bonus Plan at an exercise price of 2 pence per
share:
Name Position Number of
Options
Nicholas Staples Director of Corporate Affairs 42,553
Sally Waterman Director of Research & Development 31,914
Following the above grant of options, the above Persons Discharging Managerial
Responsibility hold options over the following number of Ordinary Shares:
Ian Scoular 972,894
Nicholas Staples 549,163
Sally Waterman 660,373
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Protherics PLC announces Director/PDMR Shareholding - 2
| Source: Protherics PLC
Cheshire, UK--(Marketwire - June 12, 2007) -